Zentalis Pharmaceuticals Inc

Geschlossen

4.69 5.16

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.44

Max

4.55

Schlüsselkennzahlen

By Trading Economics

Einkommen

-136K

-35M

EPS

-0.503

Angestellte

106

EBITDA

2.2M

-35M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+56.95% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

33M

328M

Vorheriger Eröffnungskurs

-0.47

Vorheriger Schlusskurs

4.69

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Juli 2026, 23:51 UTC

Bitcoin and Ethereum rise as weak U.S. jobs data dims Fed rate hike expectations, while Asian markets react positively to easing geopolitical tensions.

5. Juli 2026, 23:51 UTC

Bitcoin and Ethereum see positive returns amid weak U.S. jobs data and stable Eurozone activity, while geopolitical tensions ease.

5. Juli 2026, 23:51 UTC

Bitcoin and Ethereum rise as U.S. jobs data dims Fed rate hike expectations ahead of key FOMC minutes release.

5. Juli 2026, 23:51 UTC

Disappointing U.S. jobs report dampens interest rate hike expectations, impacting investor sentiment and market stability ahead of key economic releases.

5. Juli 2026, 23:51 UTC

ISM Services PMI Forecasted at 54.2 Indicates Continued Growth Amid Economic Uncertainties and Potential Fed Policy Shifts

5. Juli 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading higher during Sunday’s session, continuing its upward trajectory since Saturday's close. The asset remains above its 20-day moving average.

5. Juli 2026, 23:41 UTC

Canada's Full-Time Employment Change Data Release on July 10 Sparks Market Focus Amid Economic Uncertainty and Government Initiatives.

5. Juli 2026, 23:41 UTC

Canada's Part-Time Employment Change Data Release on July 10, 2026, Could Signal Economic Health Amid Government Policy Announcements.

5. Juli 2026, 23:41 UTC

Canada's unemployment rate data release on July 10, 2026, expected to show slight improvement at 6.6%, amid mixed signals in job growth and inflation concerns impacting monetary policy.

5. Juli 2026, 23:41 UTC

Canada's Employment Change Report Forecasts 10,000 Job Increase Amid Mixed Market Sentiment and Economic Challenges

5. Juli 2026, 23:41 UTC

Canada's Labor Force Participation Rate Release Amid Growing Concerns Over Job Security Due to AI and Automation

5. Juli 2026, 23:31 UTC

Macro News
Correlated Moves

Silver prices are rising, supported by a recovery in gold and recent oil supply increases. The U.S. dollar's strength may limit upward momentum.

5. Juli 2026, 23:31 UTC

Correlated Moves

XRP is trading roughly flat amid broader market sentiment, with Bitcoin moving moderately. The cumulative price change since Saturday remains minimal.

5. Juli 2026, 23:22 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Reflect Strong Performance Amid Trade Tensions and Inflationary Pressures

5. Juli 2026, 23:22 UTC

U.S. Balance of Trade report on July 7 forecasts a $78.8 billion deficit, raising concerns over persistent trade imbalances and potential impacts on monetary policy amid cautious market sentiment.

5. Juli 2026, 23:22 UTC

U.S. Imports Data Release on July 7 Expected to Show Continued Growth Amid Tariff Impacts and Supply Chain Adjustments

5. Juli 2026, 23:22 UTC

Brazil's July 10 inflation rate release draws market attention amid global economic concerns and potential volatility.

5. Juli 2026, 23:22 UTC

Mexico's July Inflation Rate Release Expected to Show Stabilization Around 3.94%, Influencing Future Banxico Policy Decisions

5. Juli 2026, 23:22 UTC

Brazil's June Inflation Rate Expected to Rise, Heightening Market Volatility Ahead of July 10 Release

5. Juli 2026, 23:22 UTC

Mexico's June Inflation Rate Release on July 9 Expected to Influence Monetary Policy Amid Global Economic Concerns.

5. Juli 2026, 23:22 UTC

Canada's Balance of Trade data set for July 7, 2026, anticipates a C$2.4 billion surplus amid strong export activity and cautious optimism despite global uncertainties.

5. Juli 2026, 23:11 UTC

USD/HKD is trading roughly flat after-market, with no specific news identified. Anticipation surrounds upcoming FOMC minutes and inflation data.

5. Juli 2026, 23:02 UTC

Macro News
Correlated Moves

The U.S. dollar has recovered against the Canadian dollar, leading to a slight gain in USD/CAD after-market trading.

5. Juli 2026, 23:02 UTC

Gold and silver are trading lower during Sunday’s session, continuing a downward trend since Friday's close. Market participants await key economic data.

5. Juli 2026, 23:01 UTC

Correlated Moves

Silver/AUD is trading higher, supported by gold's gains and reduced interest rate hike expectations following weaker job growth data.

5. Juli 2026, 23:01 UTC

Correlated Moves

Gold/NZD is trading higher, supported by rising gold prices against the U.S. dollar and market volatility ahead of key economic data releases.

5. Juli 2026, 23:01 UTC

Correlated Moves

Silver/GBP is trading higher, reflecting gains in gold prices. The recent trend includes four consecutive sessions of closing higher.

5. Juli 2026, 23:01 UTC

Correlated Moves

Silver/CHF is trading higher, reflecting gains from correlated movements in gold. The upward trend continues after four consecutive sessions of increases.

5. Juli 2026, 23:01 UTC

Correlated Moves

Gold/HKD is higher, supported by positive market sentiment and a rise in silver. Weaker job growth data has reduced expectations for immediate interest rate hikes.

5. Juli 2026, 23:01 UTC

Correlated Moves

Silver/CAD is higher, reflecting gains alongside rising gold prices. The asset has seen four consecutive sessions of higher closes amid significant volatility.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

56.95% Vorteil

12-Monats-Prognose

Durchschnitt 7 USD  56.95%

Hoch 10 USD

Tief 4 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

3

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat